Table 1 Baseline characteristics of study patients

Age, years

58.32 ± 12.29

54.93 ± 9.91

59.55 ± 17.36

58.82 ± 9.50

< 0.001

Male, n (%)

3078 (71.1)

594 (76.5)

802 (69.0)

1682 (70.3)

0.001

BMI, kg/(m²)

25.85 ± 3.10

25.34 ± 3.12

25.83 ± 3.10

26.23 ± 3.03

< 0.001

Family history of CAD, n (%)

608 (14.0)

128 (16.5)

152 (13.1)

328 (13.7)

0.082

Smoking, n (%)

2343 (54.1)

412 (53.1)

636 (54.7)

1317 (55.1)

0.003

Drinking, n (%)

1425 (32.9)

273 (35.2)

363 (31.2)

789 (33.0)

0.189

Hypertension, n (%)

2845 (65.7)

494 (63.7)

746 (64.1)

1605 (67.1)

0.058

FPG, mmol/L

6.37 ± 1.99

4.79 ± 0.42

6.62 ± 2.12

6.77 ± 1.93

0.006

HbA1C,  %

6.67 ± 1.22

5.37 ± 0.23

6.02 ± 0.25

7.40 ± 1.31

0.002

TC, mmol/L

4.08 ± 1.05

4.01 ± 1.01

4.04 ± 1.04

4.11 ± 1.06

0.02

HDL-C, mmol/L

1.06 ± 0.29

1.07 ± 0.31

1.04 ± 0.28

1.06 ± 0.29

0.033

Non-HDL-C, mmol/L

2.89 (2.3–3.59)

2.78 (2.21–3.53)

2.88 (2.34–3.57)

2.92 (2.31–3.64)

0.013

LDL-C, mmol/L

2.44 ± 0.89

2.38 ± 0.87

2.43 ± 0.87

2.46 ± 0.91

0.081

TG, mmol/L

1.46 (1.09–2.02)

1.36 (0.99–1.89)

1.46 (1.12–2.02)

1.50 (1.11–2.06)

0.002

CRC, mmol/L

0.52 (0.36–0.73)

0.48 (0.34–0.68)

0.52 (0.36–0.73)

0.54 (0.37–0.75)

0.001

MRC, mmol/L

0.50 (0.36–0.69)

0.47 (0.34–0.66)

0.48 (0.36–0.67)

0.52 (0.37–0.71)

< 0.001

Lp(a), mg/dL

15.10 (6.72–36.12)

14.92 (6.91–35.71)

14.86 (6.42–34.04)

15.35 (6.87–37.35)

0.334

ApoA1, g/L

1.33 ± 0.29

1.32 ± 0.31

1.33 ± 0.28

1.33 ± 0.29

0.685

ApoB, g/L

0.91 ± 0.29

0.89 ± 0.28

0.91 ± 0.27

0.91 ± 0.30

0.356

HsCRP, mg/L

1.36 (0.74–2.87)

1.09 (0.62–2.36)

1.41 (0.77–2.96)

1.45 (0.77–3.06)

0.001

Baseline statin use, n (%)

2621 (60.5)

457 (58.9)

681 (58.6)

1483 (62.0)

0.085

Baseline ezetimibe use, n (%)

463 (10.7)

76 (9.8)

120 (10.3)

267 (11.2)

0.502

Follow-up statin, n (%)

4201 (97.0)

745 (96.0)

1132 (97.3)

2324 (97.2)

0.323

Antidiabetic drug

 OADs, n (%)

1468 (33.9)

–

–

1468 (61.4)

–

 Insulin, n (%)

789 (18.2)

–

–

789 (33.0)

–